Researchers at the University of Utah Health have discovered that ceramide lipid molecules trigger acute kidney injury (AKI) by disrupting mitochondrial function, and have successfully prevented kidney damage in mice using experimental compounds targeting ceramide metabolism.
Published in Cell Metabolism, the study demonstrates that inactivating ceramides preserves mitochondrial integrity and renal function, offering a potential therapeutic strategy for a condition that affects over half of ICU patients and currently lacks effective drug treatments.
Mechanistic Insight and Biomarker Discovery
The research team, led by Dr. Scott Summers, Distinguished Professor and Chair of Nutrition & Integrative Physiology, found that ceramide levels spike dramatically in both mouse models and human urine samples following kidney injury.
These elevations correlated strongly with injury severity, suggesting urinary ceramide levels could serve as an early biomarker for AKI. “Ceramide levels rise rapidly after kidney damage and directly reflect injury severity,” said first author Dr. Rebecca Nicholson, who conducted the research as a graduate student at U of U Health.
This discovery could help identify high-risk patients before clinical symptoms appear, particularly those undergoing procedures like cardiac surgery where AKI incidence reaches 25%.
Therapeutic Intervention and Genetic Validation
Researchers employed two complementary approaches to confirm ceramide’s pathogenic role:
Genetic modification: Creating “super mice” with altered ceramide production pathways that resisted AKI even under stress conditions
Pharmacological intervention: Pretreating mice with a ceramide-reducing drug candidate developed by Centaurus Therapeutics (co-founded by Dr. Summers), which preserved renal function, maintained normal activity levels, and prevented mitochondrial damage
Mitochondrial Protection as Key Mechanism
The study revealed that ceramides cause kidney damage primarily by disrupting mitochondrial structure and function. Injured kidney cells showed severely deformed mitochondria with impaired energy production.
Both genetic and pharmacological interventions that modified ceramide metabolism maintained mitochondrial health and function even under stress conditions, explaining the observed protective effects.
Clinical Implications and Future Directions
“The compound we used is closely related to ceramide-reducing drugs already in human clinical trials,” noted Dr. Summers, while cautioning that mouse results don’t always directly translate to humans.
If validated in human studies, this approach could be proactively administered to high-risk patients—such as those undergoing cardiac surgery—to prevent AKI development. Additionally, since the therapy works by preserving mitochondrial health, it might have applications for other conditions involving mitochondrial dysfunction, including heart failure, diabetes, and fatty liver disease.
Research Support and Publication
The study, titled “Therapeutic Remodeling of the Ceramide Backbone Prevents Renal Injury,” appears in Cell Metabolism. Research support was provided by the National Institutes of Health, Juvenile Diabetes Research Foundation, Burroughs Wellcome Fund, American Diabetes Association, American Heart Association, Margolis Foundation, and the University of Utah Diabetes and Metabolism Research Center.
Related topics:
